Dive Brief:
- Pfizer CFO Dave Denton will step down from his post on Aug. 15 “for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted,” the company said Thursday in a press release.
- The New York City-based pharmaceutical giant named Cecile Guegan, now SVP of finance, global biopharmaceutical business, as interim CFO, effective Aug. 16 as the company undertakes an internal and external search for Denton’s successor.
- “Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven, and Metsera, that will serve Pfizer well for years to come,” CEO and Chairman Albert Bourla, said in a statement in the release. “We wish him the very best as he returns to the consumer goods industry.”
Dive Insight:
Denton will be leaving a pharmaceutical industry that is facing very different challenges than those it faced when he arrived in 2022 — including a rise in skepticism around vaccines and drug-makers driven in part by the Make America Healthy Again movement.
Denton moved to Pfizer's top finance seat from his post as CFO for retailer Lowe’s Companies. The news coincided with a leadership change at fellow vaccine-maker Moderna at a time when easing COVID-19 pandemic pressures appeared to be paving the way for executive exits, sister publication CFO Dive previously reported.
Even as the success of the company’s Covid vaccine and virus drug Paxlovid gave the company a $28 billion war chest, investors were “impatient for an encore,” to its “Covid franchise,” Bloomberg reported on Oct. 4, 2022.
During Denton’s tenure, the company has sought to pivot by expanding its offerings in part through acquisitions. That included its purchase of Seagen and its cancer medicines in a deal valued at $43 billion in 2023. That same year, it also cut spending and staff as it adjusted to lower demand for its Covid offerings, BioPharma Dive reported at the time.
In its first quarter this year, Pfizer’s oncology drugs Padcev and Lorbrena were “growing strongly” and helping to offset a 60% decline in covid revenue, Morningstar’s Karen Andersen wrote in a May 5 analyst note. “Pfizer's solid performance in the first quarter sets it up nicely to meet its guidance for the full year, regardless of swings in demand this fall for covid vaccines and treatments,” Andersen wrote.
Despite its recent challenges, Pfizer remains a top tier company and will likely draw its new CFO from another big name public company, according to Josh Crist, co-managing partner of the boutique executive search firm Crist Kolder. “This is not a company that’s going to struggle for CFO candidates,” Crist said in an interview. “There will be plenty.”
Denton’s 2025 compensation totaled $9.67 million, including a $1.38 million salary, compared to a total of $8.1 million in 2024, according to a March proxy filing.
Crist declined to speculate on who might be considered for the job but a number of veteran pharmaceutical finance executives have recently left companies, albeit stating retirement as the reason. They include Peter Griffith, who announced his retirement from Thousand Oaks, California-based Amgen in May and Germany-based Bayer AG CFO Wolfgang Nickl, who stepped down from the finance post last month.
Guegan, 55, who will take on the CFO role temporarily, has worked at Pfizer for more than two decades. She is currently directly responsible for financial operations and reporting of the company’s biopharmaceutical business. Guegan holds a master’s degree in business from Brest Business School.
The company said Denton’s departure is not related to financial or operating results or any disagreements with the company on financial, operational, accounting or reporting policies or practices.
Pfizer did not immediately respond to a request for further comment.
